Rodeo Therapeutics
Facts
- HQ
- Seattle
- Sectors
- Biotech, Regenerative medicine, Pharmaceuticals
- Stage
- startup
- Members see funding amounts. .
Is this your organization? Claim it
Seattle Biotech OncoResponse Raises $40.6M Series C to Develop Antibody-Based Cancer Treatments
Seattle biotech OncoResponse raised $40.6 million in a Series C round to develop antibody-based cancer immunotherapies, leveraging antibodies from patients with strong immunotherapy responses. Led by CEO Clifford Stocks, the company has now raised nearly $110 million since its 2015 launch.
Amgen to buy Seattle startup Rodeo Therapeutics for $55M upfront, up to $666M more in milestones
Amgen agreed to acquire Seattle biotech Rodeo Therapeutics, which develops small-molecule therapies to repair and regrow tissues, for $55 million upfront plus up to $666 million in contingent payments. Rodeo, led by CEO Thong Le and founded by Sanford Markowitz, Stanton Gerson and Joseph Ready, has backing from investors including AbbVie, Lilly, Arch Venture Partners and Johnson & Johnson and had raised over $14 million.
Seattle’s Rodeo Therapeutics raises $4.3M more for regenerative therapies, joining prior $3.7M infusion
Rodeo Therapeutics, a Seattle regenerative medicine startup co-founded by Drs. Sanford Markowitz, Stanton Gerson, and Joseph Ready, has added $4.3 million to an earlier $3.7 million cash infusion, building on a $5.9 million Series A from 2017. The company is developing therapies for inflammatory bowel disease and treatments to accelerate cell growth after stem cell transplants, with investors including AbbVie, Lilly, Arch Venture Partners and Johnson & Johnson.
See all 5 stories, episodes and videos about Rodeo Therapeutics.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events